Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 3/20 | 0.47 |
| ▸ | RORC | P51449 | 3/20 | 0.45 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.44 |
| ▸ | NAMPT | P43490 | 1/20 | 0.43 |
| ▸ | USP30 | Q70CQ3 | 4/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.41 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29638830 | 1.00 | TACR1 (0.47) | TACR1RORCGPR119NAMPTUSP30 | |
| SCHEMBL20589200 | 0.84 | S1PR5 (0.40) | TACR1 | |
| SCHEMBL20588202 | 0.84 | S1PR5 (0.40) | TACR1 | |
| SCHEMBL20585676 | 0.84 | S1PR5 (0.40) | TACR1 | |
| SCHEMBL20585678 | 0.84 | S1PR5 (0.40) | TACR1 | |
| SCHEMBL20585675 | 0.84 | S1PR5 (0.40) | TACR1 | |
| SCHEMBL20589198 | 0.84 | S1PR5 (0.40) | TACR1 | |
| SCHEMBL18428984 | 0.80 | GPR119 (0.56) | GPR119USP30ATMNPC1ALDH1A1 | |
| SCHEMBL23830783 | 0.79 | USP30 (0.48) | RORCGPR119NAMPTUSP30ATM | |
| SCHEMBL20116389 | 0.77 | RECQL (0.50) | RORCGPR119NAMPTUSP30ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11352342-B2 | Pharmaceutical compounds | HEPTARES THERAPEUTICS LIMITED (GB) | 2022-06-07 | — | — | US | disclosed |
| US-20210040067-A1 | PHARMACEUTICAL COMPOUNDS | NXERA PHARMA UK LIMITED (GB) | 2021-02-11 | — | — | US | disclosed |
| US-10752610-B2 | Pharmaceutical compounds | HEPTARES THERAPEUTICS LIMITED (GB) | 2020-08-25 | — | — | US | disclosed |
| US-20190276437-A1 | PHARMACEUTICAL COMPOUNDS | NXERA PHARMA UK LIMITED (GB) | 2019-09-12 | — | — | US | disclosed |
| US-10329278-B2 | Pharmaceutical compounds | HEPTARES THERAPEUTICS LIMITED (GB) | 2019-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210040067-A1 | PHARMACEUTICAL COMPOUNDS | CHRM1, CHRM2, CHRM4 | TACR1 54/4885RORC 609/4885GPR119 107/4885 |
| US-11352342-B2 | Pharmaceutical compounds | CHRM1, CHRM2, CHRM4 | TACR1 54/4885RORC 609/4885GPR119 107/4885 |
| US-10329278-B2 | Pharmaceutical compounds | CHRM1, CHRM2, CHRM4 | TACR1 49/4885RORC 570/4885GPR119 102/4885 |
| US-20190276437-A1 | PHARMACEUTICAL COMPOUNDS | CHRM1, CHRM2, CHRM4 | TACR1 54/4885RORC 609/4885GPR119 107/4885 |
| US-10752610-B2 | Pharmaceutical compounds | CHRM1, CHRM2, CHRM4 | TACR1 54/4885RORC 609/4885GPR119 107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.